熱門資訊> 正文
AN2 Therapeutics GAAP EPS—0.57美元击败0.17美元
2024-03-29 18:57
- AN2 Therapeutics press release (NASDAQ:ANTX): Q4 GAAP EPS of -$0.57 beats by $0.17.
- The Company had cash, cash equivalents, and investments of $134.5 million at December 31, 2023.
More on AN2 Therapeutics
- Spotlight On Nvidia, Walmart, Palo Alto Networks And CAGNY Conference
- AN2 Therapeutics reports FY results
- AN2 Therapeutics extends losses as Leerink cuts on trial setback
- Seeking Alpha’s Quant Rating on AN2 Therapeutics
- Historical earnings data for AN2 Therapeutics
風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。